Member Info for Dunnieboy

TR64, don’t quite understand the AML comment?

TR64, if you read the latest accounts out only last week, Vir have just transferred the license under a agreement made earlier this year, I feel your missing the point, VIr have not been proactive in promoting Sotrovimab and that’s because to the outside world it now looks like a GSK product and that is better as they are heavyweights in terms of getting the product to market, Vir are more the finder and under the collaboration agreement GSK get to the marketplace, as we retain 72.5% net that suits just fine.
YNWA

Svoboda, I posted this earlier on stocktwits, if your interested in Vir it’s worth popping up on that site;
$VIR
I think I’ve solved the mystery of the lack of pr on Vir’s side.
Its down to brand, they are now promoting It as GSK’s Sotrovimab to play on the power of the GSK brand, any selling is much easier to promote with a heavyweight backer.
This was also in the accounts that we had signed over the license in the last quarter to GSK and received milestone payments of 177m, with a further 91m due.
This suits us perfectly as they promote it as their own, and we receive 72.5% of the net sales.
We see everyday the power of branding, McDonalds after all is a franchise, Virgin is a brand, Vir are a biotech firm not set up for selling to the end user.

fantastic article in today’s Mail on Sunday headed;
Drug to protect the one in ten who don’t respond to Covid vaccine.
It states the new add on drugs known as ‘monoclonal antibodies‘ already in use in America, Europe & Asia, also significantly enhance the effect of the vaccine in high risk groups.
They also believe it has a big roll to play as a bolt-on injection being administered every month.
They specifically mention Sotrovimab,and that GSK & companies are in talks with government but say they have been frustrated by the slow speed of approval.

Orders are currently being taken worldwide for VIr/GSK’s monoclonal antibody drug Sotrovimab, the initial batch of 2.4m is currently being distributed round the world, Europe recently ordered 220,000 doses and most countries are now negotiating re-orders.
Initially it doesn’t sound like big numbers, but bear this in mind, the price wholesale is $2100 per dose & currently it is administered intravenously, which takes time & ties up a hospital bed for a hour.
The huge orders are being put together for Sotrovimab intramuscular jab, this will take a few minutes tops and at 85% efficacy a real game changer.
They are currently working on Sotrovimab II(currently Vir 7832), which will cover all variants & can be used either as a vaccine or to treat Covid once people are infected, which suits immune compromised people.
GSK has a stake in Vir and are believed to be interested in acquiring Vir, but at the moment they have extensive collaboration agreements with Vir.
GSK’s CEO always stated about Covid treatments‘’it’s not about being the first to market, it’s about being the best’, wise words.
My advice for what it’s worth is buy a few shares in Vir Biotechnology which trades on the Nasdaq, with a current mkt of $6bn it could end up being a ten bagger according to Motley Fool.

https://www.google.com/amp/s/amp.smh.com.au/politics/federal/doctors-chemists-hubs-to-deliver-2-million-jabs-a-week-when-supply-arrives-20210806-p58giq.html

This article shows they’re now up to 13,000 treated with 100% success
https://www.arabianbusiness.com/healthcare/466763-sotrovimab-proving-success-in-uaes-fight-against-covid

TR64, Vir absolutely smashed expectations when they released the results last night, they also stated they had got another drug passed in the USA which is the next version of Sotrovimab(originally Vir 7831) currently called Vir7832.
Vir 7832 is believed that it works against any variants of Covid, importantly for use its intramuscular as opposed to iv, which would help sales as it’s quicker & just a straight forward jab.
Also they are trialling 7832 as a vaccine.
Vir was up over 11% in after hours.

Sanofi is just purchasing its partner Translate-bio, I think tr6 mentioned a while back this is what Glaxo will do with its partner Vir, they are already collaborating on multiple diseases and are just bringing Sotrovimab a Covid19 antibody therapy to the market, makes sense.

Every few days GSK & Vir are getting more authorisations worldwide for their antibody therapy Sotrovimab.
GSK receives authorization under Health Canada's Interim Order for Sotrovimab for Injection to treat COVID-19 in high-risk adults and adolescents
July 30, 2021, 7:33 pm
MISSISSAUGA, ON, July 30, 2021 /CNW/ - GSK announced today that Health Canada has granted an Interim Order authorization for Sotrovimab for Injection (sotrovimab, previously VIR-7831) for the treatment of mild to moderate COVID-19, confirmed by direct SARS-COV-2 viral testing, in adults and adolescents (12 years of age and older weighing at least 40 kg) who are at high risk for progressing to hospitalization and/or deathi

Have announced today they have secured a order for 220,000 doses of the Covid19 antibody drug, prices at $2100 a dose, this is a part of a worldwide roll out of the drug with 85% efficacy.

Thanks copied from Yahoo.
I’m in Vir and it’s share price therefore Glaxo’s investment in them has got to explode soon.

https://www.businesstimes.com.sg/government-economy/singapore-inks-advance-purchase-deal-with-gsk-for-covid-19-drug-sotrovimab?amp

Vir Biotechnology(Nasdaq) who are partners with GSK are up 13% on the week after announcing final results of Sotrovimab.

TR6, with a average of $34 I hope your right.
I do believe your right about GSK taking over Vir at some stage, Scangos of Vir & Hal Barron of GSK have collaborated many times in the past with great success, and as well as Covid19 are working on annual vaccine for Covid19 & flu, can you imagine if they brought that to market.
Vir are also doing a big conference call on their great progress with their Hepatitis B trials.
I’m into Vir and have no position in GSK, the cleverer man would probably have 25% in Vir, and 75% in GSK.
I prefer the potential upside of Vir.

Alex Brummer city editor reports;Glaxo boss will defend her position against hedge fund Elliot this week.
So it’s useful that it has just revealed a new compound Sotrovimab with Vir Biotechnology(Nasdaq), which reduces hospitalisation and death rates in Covid-19 patients.
Vir Bio is up over 12% in the last two sessions and Motley Fool believes it could be a ten bagger from these levels, it’s a great buy in my opinion.

George Scangos of Vir announced last night on a video conference for Goldman Sachs, that Glaxo & Vir were working on a ‘single dose’ vaccine for Covid & Flu, he said to date it’s has shown ‘surprisingly good results’, imagine if successful it was a annual vaccination.

Previous message should of stated VIR up 16% pre-market.

The EUA news is not going to have a initial impact on a giant like GSK but VIR is showing up 26% pre-market, but it will show that GSK are making great investments I younger co’s

Just been granted for Sotrovimab a antibody that has been developed by Glaxo & Vir for Covid19 with 85% efficacy.